Assisted Reproduction Technology Devices Market Industry Research Report 2024

Assisted reproductive technology (ART) is a procedure used to achieve pregnancy. ART is used to avoid the fertility problems while perpetuating genetic connection. World’s first test tube baby was born in Britain on 25 July 1978 by In-vitro fertilization (IVF). Since then, more than one million babies have been born as the result of assisted reproductive technology. It is observed that infertility affects almost 80 million people worldwide. Overall, one in ten couples suffers with primary or secondary infertility, whereas the infertility rates varies from 5.0% to 30.0% worldwide. Human reproductive technologies came into existence due to rise in infertility rate.

Browse Global Strategic Business Report:
http://www.transparencymarketresearch.com/assisted-reproduction-technology-devices-market.html

Based on the technology, the ART devices market can be segmented as follows:

In-vitro fertilization (IVF)
Intracytoplasmic sperm injection (ICSI)
Gamete intrafallopian transfer (GIFT),
Zygote intrafallopian transfer (ZIFT)
Intrauterine insemination (IUI)
Surrogacy
According to the Centers for Disease Control and Prevention (CDC), in 2014, there were around 208,604 ART cycles performed at 458 reporting clinics in the United States, in which 57,323 were live births and 70,354 were live born infants. Overall, of the 208,604 ART cycles performed in 2014, 35,406 were banking cycles in which the intent of the ART cycle was to freeze all resulting eggs or embryos for future ART cycles. It is observed that the use of ART is still rare than its potential demand among people, however its use has been reported to be doubled over the past decade. Relatively 1.6% of all infants born every year are conceived using ART, in the United States.

Based on end users, the ART devices market can be segmented as follows:

Fertility and surgical centers
Hospitals and research laboratories
Cryobanks
Geographically the ART devices market can be segmented as follows:

North America
Europe
Asia Pacific
LAMEA
Middle East & Africa
Europe contributed the largest share in the ART devices market owing to high demand, increasing usage of ART devices and rapidly rising geriatric population. North America market is experiencing significant growth rate due to technological advancements and favorable government initiatives. According to Centers for Disease Control and Prevention (CDC), national public health action plan was developed in June 2014 for the prevention management and detection of infertility. The aim of the policy was to improve the efficacy and safety of infertility treatment. As per the data available in the public databases nearly 588,629 ART cycles were reported in the Europe (33 countries) and nearly 151,923 cycles were reported from the United States. Germany, the U.K., Spain, and Italy are the most active countries for ART in Europe. Asia Pacific is expected to be the fastest growing region due to increasing awareness, late family planning, availability of advanced fertility services, and low fertility rate. Countries in the Latin American region is also experiencing considerable growth in ART devices market owing to increasing healthcare infrastructure and growing demand for quality and safety healthcare services by the patient.

Assisted reproductive technology devices market is anticipated to grow further due to increasing number of government support for infertility procedures, rapidly growing infertility cases, rising disposable income, increasing number of smokers, and rise in the obese population. One in six couples globally experience some form of infertility. It was observed that around 5 million babies had been born from IVF and other reproductive technologies worldwide as or 2015. Due to birth defects risk, disposables of embryo, rise in ethical issues towards ART assisted babies and expensive treatment could restrain the global assisted reproductive technology market.

Major players operating in the global assisted reproductive technology devices market includes Parallabs, Cryolab Ltd., Irvine Scientific, European Sperm Bank Cosmos Biomedical Limited, Microm UK Limited, Origio.

Download Exclusive Brochure of This Report :
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14330

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: www.transparencymarketresearch.com

This release was published on openPR.